[
  {
    "Year": "2024",
    "TherapeuticArea": " Neurology ",
    "Disease": "Metachromatic leukodystrophy(MLD)",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2024",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2024",
    "TherapeuticArea": " Immunology ",
    "Disease": "WHIM Syndrome",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2024",
    "TherapeuticArea": " Hematology ",
    "Disease": "Sickle Cell Disease (SCD)",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2024",
    "TherapeuticArea": " Hematology ",
    "Disease": "Congenital thrombotic thrombocytopenic purpura (cTTP)",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2024",
    "TherapeuticArea": " Dermatology ",
    "Disease": "Epidermolysis bullosa",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": "Orthopaedics",
    "Disease": "fibrodysplasia ossificans progressiva",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": " Neurology ",
    "Disease": "Rett Syndrome",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": " Neurology ",
    "Disease": "Friedreich's ataxia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": "Metabolic",
    "Disease": "Alpha-mannosidosis",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": "Metabolic",
    "Disease": "Acid sphingomyelinase deficiency",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": " Immunology ",
    "Disease": "CHAPLE Disease",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": " Immunology ",
    "Disease": "Activated PI3K delta syndrome",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2023",
    "TherapeuticArea": " Dermatology ",
    "Disease": "Epidermolysis bullosa",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2022",
    "TherapeuticArea": "Orthopaedics",
    "Disease": "Achondroplasia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2022",
    "TherapeuticArea": " Neurology ",
    "Disease": "Cyclin-dependent\nkinase-like 5 ",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2022",
    "TherapeuticArea": " Neurology ",
    "Disease": "Cerebral adrenoleukodystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2022",
    "TherapeuticArea": " Hepatology ",
    "Disease": "Familial intrahepatic cholestasis",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2022",
    "TherapeuticArea": " Hematology ",
    "Disease": "ÃŸ-thalassemia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2021",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2021",
    "TherapeuticArea": " Nephrology ",
    "Disease": "Primary hyperoxaluria type 1",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2021",
    "TherapeuticArea": "Metabolic",
    "Disease": "Molybdenum Cofactor Deficiency",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2021",
    "TherapeuticArea": " Immunology ",
    "Disease": "Congenital athymia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2021",
    "TherapeuticArea": " Hematology ",
    "Disease": "Hypoplasminogenemia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": "Oncology",
    "Disease": "Neuroblastoma/neurofi bromatosis type 1",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": "Oncology",
    "Disease": "Neuroblastoma/neurofi bromatosis type 1",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": " Pulmonology ",
    "Disease": "Cystic fibrosis",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme"
  },
  {
    "Year": "2020",
    "TherapeuticArea": " Neurology ",
    "Disease": "Spinal muscular atrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": " Genetic",
    "Disease": "Progeria",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2020",
    "TherapeuticArea": " Endocrinology ",
    "Disease": "Pro-opiomelanocortin (POMC)",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2019",
    "TherapeuticArea": " Pulmonology ",
    "Disease": "Cystic fibrosis",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme"
  },
  {
    "Year": "2019",
    "TherapeuticArea": " Neurology ",
    "Disease": "Spinal muscular atrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2019",
    "TherapeuticArea": "Metabolic",
    "Disease": "Lysosomal Acid Lipase deficiency",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2018",
    "TherapeuticArea": "Hematology",
    "Disease": "Hemophagocytic lymph ohistiocytosis",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2018",
    "TherapeuticArea": " Ophthalmology ",
    "Disease": "Biallelic RPE65 mutation",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2018",
    "TherapeuticArea": " Neurology ",
    "Disease": "Dravet Syndrome or Lennox-Gastaut Syndrome",
    "FDA-Approved Therapy Prior to 2012": "Felbatol; Onfi; Lamictal; Topamax; Banzel"
  },
  {
    "Year": "2018",
    "TherapeuticArea": "Metabolic",
    "Disease": "Hypophosphatasia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2018",
    "TherapeuticArea": " Immunology ",
    "Disease": "Adenosine DeaminaseSevere Combined Immunodeficiency",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2017",
    "TherapeuticArea": " Oncology ",
    "Disease": "Acute lymphoblastic leukemia",
    "FDA-Approved Therapy Prior to 2012": "Arranon; Clolar"
  },
  {
    "Year": "2017",
    "TherapeuticArea": " Neurology ",
    "Disease": "Spinal muscular atrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2017",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2017",
    "TherapeuticArea": " Neurology ",
    "Disease": "Batten disease",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2017",
    "TherapeuticArea": "Metabolic",
    "Disease": "Mucopolysaccharidosis Type VII",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2016",
    "TherapeuticArea": " Neurology ",
    "Disease": "Duchenne muscular dystrophy",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2015",
    "TherapeuticArea": "Oncology",
    "Disease": "Neuroblastoma/neurofi bromatosis type 1",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2015",
    "TherapeuticArea": "Metabolic",
    "Disease": "Hypophosphatasia",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2015",
    "TherapeuticArea": "Metabolic",
    "Disease": "Hereditary orotic aciduria",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2015",
    "TherapeuticArea": " Gastroenterology ",
    "Disease": "Bile acid synthesis disorders",
    "FDA-Approved Therapy Prior to 2012": "None"
  },
  {
    "Year": "2014",
    "TherapeuticArea": "Metabolic",
    "Disease": "Morquio A syndrome",
    "FDA-Approved Therapy Prior to 2012": "None"
  }
]